A multi-center Phase III study discussed at the 2009 meeting of the American Urological Association,
[1] has demonstrated that the risk for bone fractures in men on androgen deprivation therapy (ADT) can be reduced by using toremifene (Acapodene).
Men, fighting advanced prostate cancer, often receive l